Distinguished in WT1-Related Wilms Tumor Syndromes

Dr. David S. Morris

Urology
Urology Associates
Urology Associates PC
2801 Charlotte Ave, 
Nashville, TN 
Accepting New Patients
Offers Telehealth

Distinguished in WT1-Related Wilms Tumor Syndromes
Urology Associates
Urology Associates PC
2801 Charlotte Ave, 
Nashville, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Morris is an Urologist in Nashville, Tennessee. Dr. Morris is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Urinary Tract Infection (UTI), Ureteroscopy, and Reconstructive Urology Surgery. Dr. Morris is currently accepting new patients.

His clinical research consists of co-authoring 23 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Urology
Licenses
Student in an Organized Health Care Education/Training Program in MI
Hospital Affiliations
Tristar Horizon Medical Center
Highpoint Health-Sumner With Ascension Saint Thoma
Tristar Hendersonville Medical Center
Tristar Summit Medical Center
Tristar Skyline Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
US Health and Life
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

UROLOGY ASSOCIATES PC
2801 Charlotte Ave, Nashville, TN 37209
Call: 615-250-9200
Other Locations
UROLOGY ASSOCIATES PC
107 Glen Oak Blvd, Suite 100, Hendersonville, TN 37075
Call: 615-822-9336

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


9 Clinical Trials

CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer
CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2025
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Terminated
Publish Date: December 09, 2024
Intervention Type: Drug
Study Drugs: Tazemetostat, Abiraterone/prednisone, Enzalutamide
Study Phase: Phase 1/Phase 2
A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence
A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence
Enrollment Status: Active_not_recruiting
Publish Date: November 04, 2024
Intervention Type: Drug
Study Drug: UGN-102
Study Phase: Phase 3
A Phase 3b, Open-Label, Single-Arm, Multicenter Study to Assess the Feasibility of Home Instillation of UGN-102 for Treatment of Patients With Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) at Intermediate-Risk (IR) of Recurrence
A Phase 3b, Open-Label, Single-Arm, Multicenter Study to Assess the Feasibility of Home Instillation of UGN-102 for Treatment of Patients With Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) at Intermediate-Risk (IR) of Recurrence
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: UGN-102
Study Phase: Phase 3
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
Enrollment Status: Terminated
Publish Date: February 05, 2024
Intervention Type: Drug
Study Drugs: VERU-111, Enzalutamide, Abiraterone, Darolutamide and Apalutamide
Study Phase: Phase 3
Long-Term Prospective Registry to Evaluate Treatment Decisions and Clinical Outcomes in Patients With Favorable Intermediate-Risk Localized Prostate Cancer Following Cell Cycle Progression (CCP) Testing (Prolaris® Test)
Long-Term Prospective Registry to Evaluate Treatment Decisions and Clinical Outcomes in Patients With Favorable Intermediate-Risk Localized Prostate Cancer Following Cell Cycle Progression (CCP) Testing (Prolaris® Test)
Enrollment Status: Terminated
Publish Date: June 23, 2022
Intervention Type: Diagnostic test
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: May 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer
A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer
Enrollment Status: Terminated
Publish Date: August 28, 2019
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
Enrollment Status: Terminated
Publish Date: August 19, 2019
Intervention Type: Biological
View 8 Less Clinical Trials

23 Total Publications

Side effect management and procedural best practices with indwelling intravesical drug-releasing systems in the treatment of bladder cancer: recommendations from expert panels.
Side effect management and procedural best practices with indwelling intravesical drug-releasing systems in the treatment of bladder cancer: recommendations from expert panels.
Journal: Current opinion in urology
Published: October 09, 2025
View All 23 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Kelvin A. Moses
Urology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Kelvin A. Moses
Urology

Vanderbilt University Medical Center

1301 Medical Ctr Dr, 
Nashville, TN 
 (1.3 miles away)
615-322-5000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Kelvin Moses is an Urologist in Nashville, Tennessee. Dr. Moses is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Penile Cancer, Renal Cell Carcinoma (RCC), Nephrectomy, and Reconstructive Urology Surgery. Dr. Moses is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Sam S. Chang
Urology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Sam S. Chang
Urology

Vanderbilt University Medical Center

1301 22nd Ave S, 
Nashville, TN 
 (1.3 miles away)
615-322-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sam Chang is an Urologist in Nashville, Tennessee. Dr. Chang is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Non-Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy. Dr. Chang is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Stanley D. Herrell
Urology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Stanley D. Herrell
Urology

Vanderbilt University Medical Center

6002 Hwy 100, 
Nashville, TN 
 (4.9 miles away)
615-936-9360
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Stanley Herrell is an Urologist in Nashville, Tennessee. Dr. Herrell is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, Nephrectomy, and Reconstructive Urology Surgery. Dr. Herrell is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Morris's expertise for a condition
ConditionClose
    • Distinguished
    • Bladder Cancer
      Dr. Morris is
      Distinguished
      . Learn about Bladder Cancer.
      See more Bladder Cancer experts
    • Boils
      Dr. Morris is
      Distinguished
      . Learn about Boils.
      See more Boils experts
    • Carbuncle
      Dr. Morris is
      Distinguished
      . Learn about Carbuncle.
      See more Carbuncle experts
    • Chromophobe Renal Cell Carcinoma
      Dr. Morris is
      Distinguished
      . Learn about Chromophobe Renal Cell Carcinoma.
      See more Chromophobe Renal Cell Carcinoma experts
    • Clear Cell Sarcoma
      Dr. Morris is
      Distinguished
      . Learn about Clear Cell Sarcoma.
      See more Clear Cell Sarcoma experts
    • Enlarged Prostate (BPH)
      Dr. Morris is
      Distinguished
      . Learn about Enlarged Prostate (BPH).
      See more Enlarged Prostate (BPH) experts
    View All 20 Distinguished Conditions
    • Advanced
    • Bilateral Hydronephrosis
      Dr. Morris is
      Advanced
      . Learn about Bilateral Hydronephrosis.
      See more Bilateral Hydronephrosis experts
    • Bladder Outlet Obstruction
      Dr. Morris is
      Advanced
      . Learn about Bladder Outlet Obstruction.
      See more Bladder Outlet Obstruction experts
    • Bladder Stones
      Dr. Morris is
      Advanced
      . Learn about Bladder Stones.
      See more Bladder Stones experts
    • Congenital Mesoblastic Nephroma
      Dr. Morris is
      Advanced
      . Learn about Congenital Mesoblastic Nephroma.
      See more Congenital Mesoblastic Nephroma experts
    • Empyema
      Dr. Morris is
      Advanced
      . Learn about Empyema.
      See more Empyema experts
    • Epididymitis
      Dr. Morris is
      Advanced
      . Learn about Epididymitis.
      See more Epididymitis experts
    View All 22 Advanced Conditions
    • Experienced
    • Balanitis
      Dr. Morris is
      Experienced
      . Learn about Balanitis.
      See more Balanitis experts
    • BRCA Positive Breast Cancer
      Dr. Morris is
      Experienced
      . Learn about BRCA Positive Breast Cancer.
      See more BRCA Positive Breast Cancer experts
    • Choriocarcinoma
      Dr. Morris is
      Experienced
      . Learn about Choriocarcinoma.
      See more Choriocarcinoma experts
    • Delayed Ejaculation
      Dr. Morris is
      Experienced
      . Learn about Delayed Ejaculation.
      See more Delayed Ejaculation experts
    • HER2 Negative Breast Cancer
      Dr. Morris is
      Experienced
      . Learn about HER2 Negative Breast Cancer.
      See more HER2 Negative Breast Cancer experts
    • Hereditary Paraganglioma-Pheochromocytoma Syndrome
      Dr. Morris is
      Experienced
      . Learn about Hereditary Paraganglioma-Pheochromocytoma Syndrome.
      See more Hereditary Paraganglioma-Pheochromocytoma Syndrome experts
    View All 34 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2025 All Rights Reserved